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Liver cyst infection (LCI) is a rare but life-threatening complica-
tion of autosomal dominant polycystic kidney disease (ADPKD)
[1]. Its diagnosis remains problematic given the lack of specific
and sensitive symptoms and signs. In 2009, Sallée et al. [2] pro-
posed diagnostic criteria: 3-day fever >38.5C, liver tenderness,
plasma C-reactive protein (CRP) levels >50 mg/L and no evi-
dence for cyst haemorrhage on computed tomography (CT). 18F-
fluorodeoxyglucose (18F-FDG) positron emission tomography
(PET) has proved useful in LCI diagnosis [3, 4]. In 2010, Kanaan et
al. [5] reported on an elevation of serum levels of carbohydrate
antigen 19-9 (CA19-9) (compared with individual baseline level)
in three kidney transplant recipients (KTRs) with ADPKD and bi-
lateral nephrectomy who presented with LCI. These observa-
tions suggested a potential utility of CA19-9 as a diagnostic
biomarker of LCI in APDKD patients.
CA19-9 is classically used as a biomarker for biliopancreatic
malignancies [6]. Serum CA19-9 may also increase in other
types of cancer as well as in non-malignant conditions [7].
Interestingly, serum levels of CA19-9 are constitutively high in
patients with polycystic liver diseases, including autosomal
dominant polycystic liver disease and ADPKD, due to a leakage
from cysts into lymphatic or capillary vessels [8, 9]. Of the
ADPKD patients, 19–44% present with elevated basal serum lev-
els of CA19-9 [5, 7, 9], with an adapted upper threshold of
106 kU/L (corresponding to the 90th percentile) [5]. Serum levels
of gamma-glutamyltransferase and the volume of liver cysts
are independent predictors for basal serum CA19-9 levels [9].
Serum CA19-9 concentrations are not influenced by the glomer-
ular filtration rate [10]. The impact of kidney transplantation
and/or immunosuppressive drugs on CA19-9 levels has not
been studied thus far.
In this study we retrospectively evaluated the clinical rele-
vance of serum CA19-9 levels in the diagnosis of LCI in ADPKD
patients (Table 1). Our work was approved by the Commission
of Biomedical Ethics of the University of Liège Hospital, Liège,
Belgium. Using our systematic computerized billing database,
we identified seven episodes of LCI in five different patients in
whom serum CA19-9 levels had been measured at the time of
LCI [using the monoclonal antibody #1116-NS-19-9 on a Cobas
e602 (Roche, Basel, Switzerland)]. Five episodes met the clinico-
biological diagnostic criteria and six showed a typical accumu-
lation of 18F-FDG around the infected cysts detected by PET/CT
imaging (n¼ 6) done after a median of 7 days [interquartile
range (IQR) 4–13) post-admission. The median age of the cohort
reached 73 years (IQR 54–79). The female:male ratio was 4:3.
The median body mass index was 26.4 kg/m2 (IQR 22.8–28.3).
Six LCI episodes occurred in KTRs. Blood analyses detected the
causative germ in six cases: Klebsiella pneumoniae (n¼ 3),
Escherichia coli (n¼ 2) and Acinetobacter species (n¼ 1). All urinaly-
ses were negative. The median CA19-9 level at the time of LCI
was 29.7 kU/L (IQR 16.2 –81.5), with four episodes within the
normal range (<34 kU/L). Baseline serum CA19-9 levels were
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available in four patients, i.e. six episodes. The median CA19-9
level at baseline, i.e. sampled at a distance from any bilio-
pancreatic digestive pathologies, reached 39.5 kU/L (IQR 28.7–
79.3), with two cases within the normal range. Among these six
LCIs, three cases (50%) showed decreased serum levels of
CA19-9 at the time of LCI compared with baseline values
(Table 1).
Despite the limited number of patients/episodes, our retro-
spective observations show that the serum levels of CA19-9—in
absolute values or in deltas relative to individual baseline
values—do not systematically increase in case of LCI in ADPKD
patients. Given the cost of CA19-9 dosage and its large inter-
and intra-individual variability in ADPKD patients at baseline
and in case of LCI, the clinical relevance of measuring serum
levels of CA19-9 in ADPKD patients with a suspected LCI is
questioned.
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Table 1. Clinical and biological features of our cohort
Patient Gender Age BMI KTR Pain Fever CRP CT PET/CT CA 19-9 bCA 19-9 DCA 19-9 Blood culture
1 F 54 22.8  þ þ 454  ND 57.2 45.7 11.5 –
2 F 77 28.3 þ   132  þ 81.5 79.3 2.2 Acinetobacter species
3 M 73 26.7 þ   283  þ 61.8 39.6 22.2 Klebsiella pneumoniae
73 26 þ þ þ 127  þ 29.7 39.6 9.9 Escherichia coli
4 F 78 26.4 þ þ þ 109  þ 16.2 28.7 12.5 Klebsiella pneumoniae
79 26.8 þ þ þ 154  þ 19.5 28.7 9.2 Klebsiella pneumoniae
5 M 67 25 þ þ þ 177  þ 29.3 ND – Escherichia coli
Age, age (years) at the time of LCI; BMI, body mass index (kg/m2); Pain, liver tenderness; Fever, temperature 38.5C for 3 days; CRP, peak value of plasma CRP within
72 h upon hospital admission (mg/L); CA 19-9, serum levels of CA 19-9 at the time of LCI (kU/L; normal range 34 kU/L); bCA 19-9, baseline serum levels of CA 19-9; DCA
19-9, difference between serum levels of CA 19-9 at the time of LCI versus baseline; Blood culture, identification of the causative germ in blood; M, male; F, female; ND,
not done; PET/CT þ, 18FDG PET imaging suggestive of LCI; CT , abdominal CT showing no cyst haemorrhage or other cause of fever.
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